AbbVie Inc. (ABBV) Financial Ratios
16 years of historical data (2010–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↑
15.18
-2% vs avg
5yr avg: 15.54
30Y Low9.1·High26.7
P/FCF
↑
20.47
↑+35% vs avg
5yr avg: 15.13
30Y Low9.0·High35.9
P/B Ratio
↑
N/A
—
5yr avg: 38.07
30Y Low13.7·High93.7
ROE
↑
6214.7%
↓+381% vs avg
5yr avg: 1293.1%
30Y Low25%·High187%
Debt/EBITDA
↓
2.45
↓-15% vs avg
5yr avg: 2.89
30Y Low2.2·High4.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ABBV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AbbVie Inc. trades at 87.0x earnings, 59% above its 5-year average of 54.6x, sitting at the 93rd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 292%. On a free-cash-flow basis, the stock trades at 20.5x P/FCF, 35% above the 5-year average of 15.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $364.6B | $405.3B | $315.1B | $274.8B | $287.3B | $240.6B | $179.3B | $131.4B | $142.5B | $155.0B | $102.1B |
| Enterprise Value | $428.5B | $469.2B | $377.4B | $322.1B | $342.3B | $308.4B | $257.9B | $158.6B | $175.5B | $183.1B | $133.9B |
| P/E Ratio → | 86.98 | 96.41 | 74.35 | 56.97 | 24.38 | 20.99 | 39.39 | 16.77 | 25.05 | 29.31 | 17.25 |
| P/S Ratio | 5.96 | 6.63 | 5.59 | 5.06 | 4.95 | 4.28 | 3.91 | 3.95 | 4.35 | 5.49 | 3.98 |
| P/B Ratio | — | — | 93.66 | 26.43 | 16.62 | 15.59 | 13.69 | — | — | 30.42 | 22.03 |
| P/FCF | 20.47 | 22.75 | 17.67 | 12.45 | 11.85 | 10.94 | 10.68 | 10.29 | 11.14 | 16.44 | 15.56 |
| P/OCF | 19.16 | 21.30 | 16.75 | 12.03 | 11.52 | 10.56 | 10.19 | 9.86 | 10.61 | 15.56 | 14.51 |
P/E links to full P/E history page with 30-year chart
ABBV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
AbbVie Inc.'s enterprise value stands at 15.2x EBITDA, roughly in line with its 5-year average of 15.5x. The Healthcare sector median is 14.0x, placing the stock at a 8% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.67 | 6.70 | 5.93 | 5.90 | 5.49 | 5.63 | 4.77 | 5.36 | 6.49 | 5.22 |
| EV / EBITDA | 15.18 | 16.62 | 21.54 | 15.01 | 12.88 | 11.66 | 14.46 | 10.57 | 21.54 | 16.58 | 12.71 |
| EV / EBIT | 21.33 | 49.44 | 57.84 | 38.01 | 21.79 | 20.01 | 44.07 | 15.53 | 26.82 | 20.63 | 14.99 |
| EV / FCF | — | 26.33 | 21.16 | 14.60 | 14.12 | 14.03 | 15.36 | 12.41 | 13.73 | 19.41 | 20.40 |
ABBV Profitability
Margins and return-on-capital ratios measuring operating efficiency
AbbVie Inc. earns an operating margin of 32.8%. Operating margins have expanded from 23.5% to 32.8% over the past 3 years, signaling improving operational efficiency. Return on equity of 6214.7% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks. ROIC of 23.9% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.2% | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% | 77.6% | 76.4% | 75.0% | 77.2% |
| Operating Margin | 32.8% | 32.8% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 33.8% | 36.4% |
| Net Profit Margin | 6.9% | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 6214.7% | 6214.7% | 62.2% | 35.1% | 72.3% | 80.9% | 187.5% | — | — | 109.1% | 138.7% |
| ROA | 3.1% | 3.1% | 3.2% | 3.6% | 8.3% | 7.8% | 3.9% | 10.6% | 8.7% | 7.8% | 10.0% |
| ROIC | 23.9% | 23.9% | 11.1% | 14.7% | 17.5% | 15.4% | 15.4% | 44.7% | 16.6% | 20.6% | 22.0% |
| ROCE | 21.5% | 21.5% | 9.5% | 12.4% | 16.4% | 15.4% | 11.6% | 22.5% | 13.3% | 17.3% | 19.0% |
ABBV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
AbbVie Inc. carries a Debt/EBITDA ratio of 2.4x, which is manageable (22% below the sector average of 3.1x). Net debt stands at $63.8B ($69.1B total debt minus $5.2B cash). Interest coverage of 3.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 20.17 | 5.78 | 3.71 | 5.03 | 6.65 | — | — | 7.33 | 7.95 |
| Debt / EBITDA | 2.45 | 2.45 | 3.87 | 2.80 | 2.41 | 2.93 | 4.88 | 4.47 | 4.95 | 3.38 | 3.50 |
| Net Debt / Equity | — | — | 18.52 | 4.55 | 3.18 | 4.39 | 6.00 | — | — | 5.51 | 6.85 |
| Net Debt / EBITDA | 2.26 | 2.26 | 3.56 | 2.20 | 2.07 | 2.56 | 4.41 | 1.81 | 4.05 | 2.54 | 3.01 |
| Debt / FCF | — | 3.58 | 3.49 | 2.14 | 2.27 | 3.08 | 4.68 | 2.13 | 2.58 | 2.98 | 4.84 |
| Interest Coverage | 3.28 | 3.28 | 2.32 | 3.81 | 7.04 | 6.36 | 2.38 | 5.72 | 4.86 | 7.72 | 8.53 |
ABBV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.67x is below 1.0, meaning current liabilities exceed current assets — though the company's $5.2B cash position helps mitigate short-term liquidity concerns. The current ratio has declined from 0.87x to 0.67x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.67 | 0.67 | 0.66 | 0.87 | 0.96 | 0.79 | 0.84 | 3.18 | 0.98 | 1.28 | 1.65 |
| Quick Ratio | 0.56 | 0.56 | 0.55 | 0.76 | 0.84 | 0.70 | 0.73 | 3.06 | 0.89 | 1.18 | 1.51 |
| Cash Ratio | 0.12 | 0.12 | 0.14 | 0.34 | 0.31 | 0.28 | 0.30 | 2.56 | 0.47 | 0.59 | 0.66 |
| Asset Turnover | — | 0.46 | 0.42 | 0.40 | 0.42 | 0.38 | 0.30 | 0.37 | 0.55 | 0.40 | 0.39 |
| Inventory Turnover | 3.68 | 3.68 | 4.04 | 4.98 | 4.87 | 5.58 | 4.65 | 4.10 | 4.81 | 4.39 | 4.04 |
| Days Sales Outstanding | — | 75.13 | 70.75 | 74.96 | 70.76 | 64.80 | 70.30 | 59.56 | 60.00 | 65.82 | 67.74 |
ABBV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AbbVie Inc. returns 3.5% to shareholders annually — split between a 3.2% dividend yield and 0.3% buyback yield. The payout ratio exceeds 100% at 275.8%, meaning the company is paying out more than it earns — this level is unsustainable long-term without earnings recovery. The earnings yield of 1.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 3.2% | 2.9% | 3.5% | 3.8% | 3.5% | 3.8% | 4.3% | 4.8% | 3.9% | 2.6% | 3.6% |
| Payout Ratio | 275.8% | 275.8% | 257.7% | 216.7% | 84.9% | 80.2% | 167.2% | 80.8% | 98.1% | 77.4% | 62.4% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.1% | 1.0% | 1.3% | 1.8% | 4.1% | 4.8% | 2.5% | 6.0% | 4.0% | 3.4% | 5.8% |
| FCF Yield | 4.9% | 4.4% | 5.7% | 8.0% | 8.4% | 9.1% | 9.4% | 9.7% | 9.0% | 6.1% | 6.4% |
| Buyback Yield | 0.3% | 0.2% | 0.5% | 0.7% | 0.5% | 0.4% | 0.5% | 0.5% | 8.4% | 0.9% | 5.9% |
| Total Shareholder Yield | 3.5% | 3.1% | 4.0% | 4.6% | 4.0% | 4.2% | 4.8% | 5.3% | 12.3% | 3.6% | 9.5% |
| Shares Outstanding | — | $1.8B | $1.8B | $1.8B | $1.8B | $1.8B | $1.7B | $1.5B | $1.5B | $1.6B | $1.6B |
Peer Comparison
Compare ABBV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ABBVYou | $365B | 87.0 | 15.2 | 20.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 JNJ | $544B | 39.0 | 18.9 | 27.4 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 MRK | $279B | 15.5 | 10.8 | 22.6 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $150B | 19.4 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 BMY | $116B | 16.5 | 9.3 | 9.0 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 LLY | $934B | 43.1 | 31.0 | 104.1 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 AMGN | $178B | 23.2 | 14.1 | 22.0 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 GILD | $166B | 351.3 | 41.3 | 16.1 | 78.3% | 5.8% | 2.3% | 3.2% | 6.0 |
 BIIB | $28B | 21.4 | 11.3 | 13.6 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 REGN | $73B | 16.9 | 17.6 | 17.9 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 SNY | $105B | 18.2 | 10.8 | 10.0 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 16 years · Updated daily
Full ABBV Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy ABBV Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See ABBV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABBV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABBV vs JNJ
Side-by-side business, growth, and profitability comparison vs Johnson & Johnson.
Start ComparisonABBV — Frequently Asked Questions
Quick answers to the most common questions about buying ABBV stock.
What is AbbVie Inc.'s P/E ratio?
AbbVie Inc.'s current P/E ratio is 87.0x. The historical average is 36.4x. This places it at the 93th percentile of its historical range.
What is AbbVie Inc.'s EV/EBITDA?
AbbVie Inc.'s current EV/EBITDA is 15.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.5x.
What is AbbVie Inc.'s ROE?
AbbVie Inc.'s return on equity (ROE) is 6214.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 88.4%.
Is ABBV stock overvalued?
Based on historical data, AbbVie Inc. is trading at a P/E of 87.0x. This is at the 93th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is AbbVie Inc.'s dividend yield?
AbbVie Inc.'s current dividend yield is 3.19% with a payout ratio of 275.8%.
What are AbbVie Inc.'s profit margins?
AbbVie Inc. has 70.2% gross margin and 32.8% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does AbbVie Inc. have?
AbbVie Inc.'s Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.